Mutational spectra of aflatoxin B <sub>1</sub> in vivo establish biomarkers of exposure for human hepatocellular carcinoma

Supawadee Chawanthayatham, Charles C. Valentine, Bogdan I. Fedeles, Edward Fox, Lawrence A. Loeb, Stuart S. Levine, Stephen L. Slocum, Gerald N. Wogan, Robert G. Croy, John M. Essigmann

Proceedings of the National Academy of Sciences · 2017 · 129 citations · 37 references

DOIFull text

Open access

Concepts

Abstract

Significance Several decades elapse between liver cancer initiation and the appearance of tumors, and there are rarely overt clues that presage the appearance of disease. There is an acute need for biomarkers of incipient carcinogenesis when the disease is clinically addressable. This work used high-fidelity DNA sequencing and a mouse model to reveal high-resolution mutational spectra of the liver carcinogen aflatoxin B 1 in histopathologically normal liver as early as 10 wk after exposure. The spectrum, which is mirrored in human liver tumors, persisted through carcinoma development more than a year later. Identification of tumor mutational spectra in a manipulable animal model affords opportunities for the efficient testing of strategies relevant to early detection, prevention, and management of human cancer.

References

37